Trials / Completed
CompletedNCT04456452
Study of Ampion for the Treatment of Adult COVID-19 Patients Requiring Oxygen Supplementation
A Randomized Controlled Trial to Evaluate the Safety of Intravenous Ampion™ in Adult COVID-19 Patients Requiring Oxygen Supplementation
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Ampio Pharmaceuticals. Inc. · Industry
- Sex
- All
- Age
- 18 Years – 89 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1 randomized study to evaluate the safety, tolerability and efficacy of IV Ampion in improving the clinical course and outcomes of patients hospitalized with COVID-19 infection who require supplemental oxygen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Ampion | Ampion, administered by intravenous infusion |
| OTHER | Standard of Care | Standard of Care |
Timeline
- Start date
- 2020-07-27
- Primary completion
- 2020-09-08
- Completion
- 2020-11-30
- First posted
- 2020-07-02
- Last updated
- 2021-01-13
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04456452. Inclusion in this directory is not an endorsement.